Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | +6.81% | +9.61% | -21.07% |
06-04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
05-15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.07% | 20.37M | |
+55.55% | 59.28B | |
+43.34% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Transcript : Lumos Pharma, Inc., 2022 Earnings Call, Mar 01, 2023